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Abstract
Background: FOXM1 regulates expression of cell cycle related genes that are essential for
progression into DNA replication and mitosis. Consistent with its role in proliferation, elevated
expression of FOXM1 has been reported in a variety of human tumour entities. FOXM1 is a gene
of interest because recently chemical inhibitors of FOXM1 were described to limit proliferation
and induce apoptosis in cancer cells in vitro, indicating that FOXM1 inhibitors could represent useful
anticancer therapeutics.
Methods: Using immunohistochemistry (IHC) we systematically analysed FOXM1 expression in
human invasive breast carcinomas (n = 204) and normal breast tissues (n = 46) on a tissue
microarray. Additionally, using semiquantitative realtime PCR, a collection of paraffin embedded
normal (n = 12) and cancerous (n = 25) breast tissue specimens as well as benign (n = 3) and
malignant mammary cell lines (n = 8) were investigated for FOXM1 expression. SPSS version 14.0
was used for statistical analysis.
Results: FOXM1 was found to be overexpressed in breast cancer in comparison to normal breast
tissue both on the RNA and protein level (e.g. 8.7 fold as measured by realtime PCR). We found a
significant correlation between FOXM1 expression and the HER2 status determined by HER2
immunohistochemistry (P < 0.05). Univariate survival analysis showed a tendency between FOXM1
protein expression and unfavourable prognosis (P = 0.110).
Conclusion: FOXM1 may represent a novel breast tumour marker with prognostic significance
that could be included into multi-marker panels for breast cancer. Interestingly, we found a positive
correlation between FOXM1 expression and HER2 status, pointing to a potential role of FOXM1
as a new drug target in HER2 resistant breast tumour, as FOXM1 inhibitors for cancer treatment
were described recently. Further studies are underway to analyse the potential interaction
between FOXM1 and HER2, especially whether FOXM1 directly activates the HER2 promoter.
Published: 6 February 2008
BMC Cancer 2008, 8:42 doi:10.1186/1471-2407-8-42
Received: 23 October 2007
Accepted: 6 February 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/42
© 2008 Bektas et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:42 http://www.biomedcentral.com/1471-2407/8/42Background
Fox (Forkhead Box) proteins, characterised by a 100
amino acid winged-helix DNA binding domain, are chor-
date transcription factors that play important roles in the
regulation of growth and development [1,2]. FOXM1 is
ubiquitously expressed in cells undergoing proliferation
[3,4]. It is required for normal coupling of DNA replica-
tion (at S phase) and chromosomal segregation (at M
phase) during cell cycle progression [5]. FOXM1 expres-
sion peaks at G2/M-transition and is believed to exert its
S-M coupling role by promoting M phase entry and sup-
pressing DNA re-replication [6].
FOXM1 is localised mainly in the cytoplasm during late
G1 and S phases, but is found to be phosphorylated and
translocated to the nucleus before cells entry into the G2/
M phase. Activation of the Raf/MEK/MAPK pathway is
necessary for the nuclear translocation of FOXM1 protein
[6]. Consistent with its role in promoting proliferation,
elevated expression of FOXM1 has recently been reported
in a variety of human tumour entities including breast [7]
and liver cancer [8]. FOXM1 depletion causes a certain
form of cell death – so called mitotic catastrophe – that
occurs during mitosis often arising from aberrant G2
checkpoint control [9]. Therefore inhibition of FOXM1
expression could represent a new target in the therapeutic
treatment of breast cancer [9].
Very recently, in vitro data have demonstrated a direct reg-
ulation of the oestrogen receptor gene (ESR1) by FOXM1
protein binding to the ESR1 promoter, thus leading to
upregulation of oestrogen receptor-alpha (ERα) expres-
sion at mRNA transcript and protein levels [10]. It is well
known that oestrogen receptors play a major role in the
regulation of growth, survival and differentiation of nor-
mal and malignant breast epithelial cells [11,12]. There-
fore the determination of breast tumour hormone
receptor status is of major importance for therapy selec-
tion [13]. Approximately 60–80% of all breast cancers
abundantly express ERα, but only two thirds of those
patients are responsive to endocrinal treatment (anti-oes-
trogen therapy). Intriguingly, a proportion of ERα-posi-
tive tumours do not respond to hormone treatment at all
(de novo resistance) whilst the majority of those tumours
that initially responded to anti-oestrogens eventually
become resistant during treatment (acquired resistance).
Most ER-resistant tumours remain ERα-positive, suggest-
ing a continued role for ERα in breast cancer cell survival
and proliferation [14,15]. The very likely development of
ER-resistance during breast cancer treatment with anti-
oestrogens, like the resistances described for treatment
with the HER2 antibody Herceptin®, emphasises that
there is an urgent need for surrogate target molecules that
may allow bypassing these resistances. Recently, numer-
ous candidate genes which are highly differentially
expressed in breast cancer have been identified by our
research group [16,17]. FOXM1 is one of these candidate
genes and has been selected for further analysis because
chemical inhibitors of this target molecule are already
available and have been shown to limit proliferation e.g.
in liver cancer cells in vivo [18,19]. Thus FOXM1 inhibitors
could represent useful new anticancer therapeutics for
breast cancer as well. So far little is known about the
expression of FOXM1 in normal and cancerous human
breast tissue. In the present study we systematically ana-
lysed the expression of FOXM1 in human breast carcino-
mas and normal breast tissue on both the mRNA and
protein level and analysed the results especially in correla-
tion to hormone receptor status, HER2 status and patient
survival data.
Methods
Patient samples on the breast cancer tissue microarray 
(TMA)
FOXM1 protein expression in breast cancer patients was
assessed using a TMA that has been previously described
[17] and that consisted of 204 breast cancer specimens
and 46 normal breast tissue specimens. The TMA con-
tained one tissue core from non-selected, formalin-fixed
and paraffin-embedded primary breast cancer specimens
diagnosed between 1994 and 2002 at the Institute of
Pathology, University of Regensburg, Germany. Patients'
age ranged from 25 to 82 years with a median age of 56
years. An experienced surgical pathologist (A.H.) evalu-
ated H&E-stained slides of all specimens prior to construc-
tion of the TMA in order to identify representative tumour
areas. Histologically, all tumours were graded according
to Elston and Ellis [20]. Clinical follow-up data, provided
by the Central Tumour Registry, Regensburg, Germany
were available for all 204 breast cancer patients with a
median follow-up period of 78 months (range 0–148
months). All patients gave informed consent for retention
and analysis of their tissue for research purposes and the
Institutional Review Board of the participating centre
approved the study. The paraffin-embedded and forma-
lin-fixed normal (n = 14) and cancerous (n = 25) breast
tissue samples for mRNA expression analysis have been
described previously [21].
Cell lines
The human mammary epithelial cell lines HMEC,
MCF10A and MCF12A as well as the breast cancerous cell
lines MCF7, T47D, ZR75-1, MDA-MB231, MDA-MB468,
MDA-MB435s, SKBR3 and BT20 were obtained from the
ATCC (Rockville, MD, USA) and cultured as previously
described [22].
RNA extraction and reverse transcription
Total RNA was isolated by use of TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA) according to the manufacturers'Page 2 of 9
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cient sections were prepared, deparaffinised and conven-
tionally re-hydrated in a decreasing alcohol-series prior to
RNA extraction. Of the obtained RNA, one μg was reverse
transcribed using the Reverse Transcription System
(Promega, Madison, WI, USA). In order to improve tran-
scription rate we mixed oligo-dT and pdN6 primers 1:2.
Semiquantitative realtime PCR
Semiquantitative PCR was performed using the LightCy-
cler system together with the LightCycler DNA Master
SYBR Green I Kit (Roche Diagnostics, Mannheim, Ger-
many) as described elsewhere [22]. To ensure experiment
accuracy, all reactions were performed in triplicate. Primer
sequences were: FOXM1 sense 5'-GAG CAC TTG GAA TCA
CAG CA-3' and antisense 5'-CAC CGG GAA CTG GAT
AGG TA-3'; GAPDH sense 5'-GAA GGT GAA GGT CGG
AGT CA-3' and antisense 5'-AAT GAA GGG CTC ATT GAT
GG-3'. Annealing temperatures for both genes were set to
60°C. Reaction specificity was controlled by post-amplifi-
cational melting curve analyses as well as by gel electro-
phoresis of the obtained products.
Immunohistochemical characterisation of the tissue 
microarray
Immunohistochemical (IHC) studies for the expression of
HER2 utilised an avidin-biotin peroxidase method with a
3,3'-diaminobenzidine (DAB) chromatogen. After anti-
gen retrieval (microwave oven for 30 min) IHC was car-
ried out in a NEXES immunostainer (Ventana, Tucson,
AZ, USA) following the manufacturer's instructions. The
following primary antibodies were used: anti-HER2
(DAKO, Hamburg, Germany; 1:400), anti-ER and anti-PR
(Novocastra, Newcastle Upon Tyne, UK; 1:20). For target
proteins the ChemMate detection kit (DAKO) was used. A
surgical pathologist (A.H.) performed a blinded evalua-
tion of the TMA slides without knowledge of clinical data.
Causes of non-interpretable results included lack of
tumour tissue and presence of necrosis or crush artefacts.
HER2 expression was scored according to the DAKO Her-
cepTest. For the evaluation of ER and PR presence, a sem-
iquantitative immunoreactivity score (IRS), as described
by Remmele and Stegner [23], was used.
FOXM1 Immunohistochemistry
The tissue microarray was subjected to immunostaining
using the Advance Kit (DAKO K4068) following the man-
ufacturer's instructions. Breast carcinomas were used as
positive controls. After deparaffinisation and re-hydration
the tissue samples were boiled in a microwave oven for 30
min in 10 mM sodium citrate buffer (pH 7.2). Endog-
enous peroxidase was blocked by Peroxidase blocking
solution (DAKO S 2023). The polyclonal primary anti-
body FOXM1 (Santa Cruz sc502) was applied (1:30) for 1
h at room temperature. In negative controls the primary
antibody was omitted. The Advance Kit HRP against rab-
bit/mouse (DakoCytomation K 4065, Carpintera, CA,
USA) was applied to signal amplification for 30 min. For
signal detection 3,3'-diaminobenzidine (DAB) was used.
Slides were counterstained with hematoxylin and after
dehydration mounted in Vitro-Clud (Langenbrinck,
Emmendingen, Germany). An experienced pathologist
(N.B.) scored the immunohistochemical staining inten-
sity according to the scoring system suggested by Rem-
mele and Stegner [23].
Statistical analysis
For statistical evaluation the SPSS software version 14.0
(SPSS GmbH Software, Munich, Germany) was used. Dif-
ferences were considered statistically significant when p-
values were < 0.05. A non-parametrically two-tailed
Mann-Whitney U-test was employed to analyse differ-
ences in expression levels. A statistical association
between clinicopathological and molecular parameters
was tested, using two-sided Fisher's exact test. Recurrence-
free (RFS) and overall survival (OS) were calculated
according to the Kaplan-Meier equation.
Results
Upregulation of FOXM1 in cancerous human epithelial 
breast cell lines
We initiated our study by investigating the level of FOXM1
mRNA expression in non-malignant and malignant
human mammary cell lines. Realtime PCR analysis
revealed a homogenous FOXM1 mRNA expression in
non-malignant mammary epithelial cell lines such as
HMEC, MCF10A and MCF12A, whereas FOXM1 mRNA
transcript levels were more heterogeneous and in total ele-
vated in cancerous cell lines (Figure 1). The metastatic
breast cancer cell line MDA-MB231 presented an excep-
tionally high level of FOXM1 expression (Fig. 1). The dif-
ference in FOXM1 expression between normal and
cancerous breast cell lines was statistically significant (P =
0.048, Mann-Whitney U-test).
Upregulation of FOXM1 in primary breast cancers
Next we analysed FOXM1 mRNA expression by realtime
PCR in primary human breast cancers (n = 25) and nor-
mal mammary samples (n = 12) derived from formalin-
fixed, paraffin-embedded tissues. In line with the expres-
sion data in breast cell lines, FOXM1 mRNA was strongly
upregulated in primary breast cancer specimens com-
pared to normal mammary epithelial tissue (Fig. 2). The
median fold change of FOXM1 upregulation in the can-
cerous tissue versus normal was 8.7 and difference in
expression between the two groups was statistically signif-
icant (P = 0.029, Mann-Whitney U-test).
FOXM1 protein expression in primary human breast 
cancer
By use of a large tissue microarray (n = 250) we investi-
gated the protein expression of FOXM1 in breast cancerPage 3 of 9
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in the nucleus as well as in the cytoplasm of benign and
malignant mammary gland epithelial cells. Expression
was absent in the fibrolipomatous stroma and in vessels.
In normal breast tissue FOXM1 expression was often
absent or weaker in the nucleus compared with breast car-
cinomas. In Figure 3(A, B) normal breast tissue is shown
with very weak FOXM1 expression in the nucleus (IRS = 1)
and weak FOXM1 expression in the cytoplasm (IRS = 4).
In ductal carcinoma in situ of high grade type (Figure 3, C
and 3D) nuclear FOXM1 expression is slightly more
intense (IRS = 2) than in normal breast tissue whereas the
cytoplasmic FOXM1 expression is strong (IRS = 9). In
invasive breast carcinomas (Figure 3, E and 3F, ductal
type) FOXM1 expression was often abundant in the
nucleus (IRS = 3) as well as in the cytoplasm (IRS = 12)
compared with normal breast tissue and ductal carcinoma
in situ. In tubular breast carcinomas (Figure 3, G and 3H),
a less frequent variant of invasive breast carcinomas with
a more favourable prognosis than invasive ductal breast
carcinomas, nuclear and cytoplasmic FOXM1 expression
(each IRS = 3) was weaker than in most invasive ductal
breast carcinomas and stronger than in most normal
breast tissues. Considering the whole tissue microarray
87% (187/204) of the breast carcinomas expressed
nuclear FOXM1 versus 42% (19/46) of normal breast tis-
sue specimens. In accordance with this number the
median nuclear immunoreactive score in breast carcino-
mas (median IRS = 3) was higher than in normal breast
tissue (median IRS = 0).
Correlation between nuclear FOXM1 and 
clinicopathological patient parameters
For statistical analysis only nuclear FOXM1 expression
was considered because FOXM1 is known to be a tran-
scriptional factor exercising its biological effect especially
in the nucleus. Nuclear FOXM1 protein with an IRS ≥ 2
was considered as positive FOXM1 expression while IRS =
0 and IRS = 1 were considered as negative FOXM1 expres-
sion. Nuclear FOXM1 expression was not associated with
tumour stage, lymph node status, histological grading,
focality or histological type of tumour (Table 1). Nuclear
FOXM1 was associated with the presence of oestrogen
receptor with marginal significance (P = 0.085) but not
with presence of progesterone receptor (P = 0.702).
Importantly, a significant association was detected
between nuclear FOXM1 and high expression of the HER2
receptor as determined by immunohistochemistry
(DAKO score 3+; P = 0.045) (Table 1).
To investigate an impact of FOXM1 overexpression on
patients' clinical outcome we calculated univariate sur-
vival probability curves with respect to immunohisto-
chemical results. We found that nuclear FOXM1
expression in breast cancer (IRS ≥ 2) shows a tendency
towards unfavourable prognosis regarding overall survival
as shown by Kaplan-Meier analysis (P = 0.110) (Table 2,
Figure 4). However, recurrence-free survival was not sig-
nificantly associated with FOXM1 overexpression (Table
2).
Discussion
Fox (Forkhead box) proteins are chordate transcription
factors with an important role for cellular events such as
regulation of cell growth and cellular development [1-3].
In accordance with the observed role of FOXM1 in cell
cycle progression and cell proliferation, elevated expres-
sion of FOXM1 has been reported in several human
tumour entities [7,8]. Recently, FOXM1 expression has
been analysed in human breast carcinomas, showing that
mRNA transcript levels of the FOXM1 gene were upregu-
lated in tumour tissue as compared to normal breast tissue
[7]. However, this study neither analysed FOXM1 protein
Elevated expression of FOXM1 mRNA in breast cancer cell linesFigur  1
Elevated expression of FOXM1 mRNA in breast cancer cell 
lines. Semiquantitative realtime PCR (LightCycler) of FOXM1 
expression was performed on reverse transcribed RNA from 
non-malignant (white bars) and malignant cell lines (black 
bars). A significant difference in expression between both 
groups was detected (P = 0.048), whereas classification of 
malignant breast cell lines into oestrogen receptor (ER) posi-
tive and negative revealed no significant coherence with 
FOXM1 expression (P = 0.655; two-tailed Mann-Whitney U-
test).Page 4 of 9
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impact of FOXM1 deregulation on patient prognosis. On
a large cohort of breast cancer specimens we performed a
first systematic expression analysis of FOXM1 on both
mRNA and protein level and subsequently studied
FOXM1 expression with respect to clinicopathological
parameters and patients' survival data.
In concordance with the data from Wonsey et al. [7]
upregulation of FOXM1 mRNA was found in paraffin-
embedded breast carcinomas compared to normal breast
tissue. Consistent with FOXM1 overexpression in human
breast tumours, malignant mammary cell lines such as
MCF7, MDA-MB231, MDA-MB468, T47D and BT20 also
exhibited increased FOXM1 levels when compared to
benign mammary cell lines (HMEC, MCF10A and
MCF12A). Interestingly upregulation of FOXM1 was
highly abundant in the breast cancer cell line MDA-
MB231, a cell line which was shown to be strongly meta-
static in nude mouse models [24]. This implicates a possi-
ble association between FOXM1 upregulation and
enhanced proliferation and invasiveness of cancer cells.
Upregulation of FOXM1 mRNA in breast tumors could be
confirmed on protein level when analysing the immuno-
histochemistry results from a tissue microarray. 87% of
breast carcinomas were shown to exhibit nuclear FOXM1
staining, compared to a percentage of 41% of normal
breast tissue specimens showing nuclear FOXM1 expres-
sion. Thus FOXM1 was shown to be upregulated on both
protein and mRNA level. The median expression level in
breast tumour tissue showed an IRS of 3 while the median
IRS of normal tissue was 0. We next correlated nuclear
FOXM1 expression with patients' survival data. Patients
with nuclear FOXM1 expression showed a tendency
towards unfavourable prognosis in overall survival analy-
sis (P = 0.110). These data have to be confirmed in a pro-
spective multi-centre trial including treatment
information on FOXM1 positive and negative patients
before FOXM1 overexpression in breast cancer can be con-
sidered as an established prognostic marker potentially
useful for stratification of patient treatment.
This is the first study showing a significant association
between nuclear FOXM1 expression and abundant expres-
sion of HER2 in breast cancer (P = 0.045). In a previous
work of Yang et al. [25] FOXO4, another member of the
Fox family, was found to inhibit HER2-activated cell
growth by mediating p27 transcription. Therefore FOXO4
was discussed as a novel anticancer agent in HER2-overex-
pressing cancers. It may be concluded that FOXM1 and
FOXO4 have opposite effects on HER2 gene expression.
The human epidermal growth factor receptor 2 (HER2)
gene is localised on chromosome 17q. It encodes a trans-
membrane tyrosine kinase receptor protein that is a mem-
ber of the epidermal growth factor receptor (EGFR)/HER
family [26]. HER2 gene amplification is found in 10–34%
of invasive breast tumours and is regarded as an impor-
tant prognostic marker indicating poor patient survival
[27]. Thus determination of the HER2 status is a very
important step in clinical routine to analyse the right ther-
apeutic strategy. Intriguingly, HER2-positive breast carci-
Upregulation of FOXM1 expression in primary breast cancerFigure 2
Upregulation of FOXM1 expression in primary breast cancer. A collection of paraffin-embedded breast carcinomas (T; n = 25) 
and normal breast tissues (N; n = 12) was analysed for FOXM1 expression by semiquantitative realtime PCR. In total, we 
detected a strong upregulation at transcript level in the tumourous tissues as compared with normal breast tissues.Page 5 of 9
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progesterone receptor status [28]. So these breast carcino-
mas will not respond to treatment regimens solely based
on anti-hormones. For this reason in a fraction of HER2-
positive breast tumours a therapy with HER2 antibodies
(Trastuzumab, Herceptin®) is applied. Nevertheless, most
of the patients develop resistance to Herceptin® during
therapy [28]. Analyses of other potential target molecules
in signalling pathways of malignant mammary cells are of
great interest and may offer alternative treatment options
for patients with Herceptin® resistance. FOXM1 may be
such a candidate molecule. Recently, FOXM1 inhibitors
were discussed as new anticancer therapeutics [18,19].
Gusarova et al. [18] showed that inhibition of FOXM1
function by a cell-penetrating ARF (26–44) peptide lead
to reduced tumour cell proliferation and angiogenesis in
hepatocellular carcinoma. These studies were based on a
mouse model. The apoptotic effect was also shown in
human hepatoma cell lines. This inhibitory effect on
FOXM1 has not been analysed for human breast cancer so
far. Further functional studies including DNA binding
studies are underway to analyse the interaction between
FOXM1 and HER2, especially whether FOXM1 directly
activates the HER2 (c-erbB-2) promoter. Recent studies
show that FOXM1 protein might affect the transcription
of oestrogen receptor alpha by binding to its promoter in
vitro [10]. However, in our study we could not detect a sig-
nificant correlation between FOXM1 expression and oes-
trogen or progesterone receptor status in human breast
Immunohistochemical expression of FOXM1 in normal breast tissue as well as in non-invasive and invasive breast tu ours using a tissue micr arrayFigure 3
Immunohistochemical expression of FOXM1 in normal 
breast tissue as well as in non-invasive and invasive breast 
tumours using a tissue microarray. (A, B) Normal breast tis-
sue is detected with very weak FOXM1 expression in the 
nucleus (IRS = 1) and weak FOXM1 expression in the cyto-
plasm (IRS = 4). (C, D) In ductal carcinoma in situ of high 
grade type nuclear FOXM1 expression is a little more 
intense (IRS = 2) than in normal breast tissue whereas the 
cytoplasmic FOXM1 expression is strong (IRS = 9). (E, F) In 
invasive breast carcinoma FOXM1 expression was often 
stronger in the nucleus (IRS = 3) as well as in the cytoplasm 
(IRS = 12) compared with normal breast tissue and ductal 
carcinoma in situ. (G, H) In tubular breast carcinoma, a rare 
variant of invasive breast carcinoma with a more favourable 
prognosis than invasive ductal breast carcinoma, nuclear and 
cytoplasmic FOXM1 expression (each IRS = 3) was weaker 
than in most invasive ductal breast carcinomas and stronger 
than in most normal breast tissues. Magnifications: A, C, E, G: 
100×; B, D, F, H: 400×.
Breast cancer patients expressing nuclear FOXM1 show a tenden y towards unfavou able prognosisFigure 4
Breast cancer patients expressing nuclear FOXM1 show a 
tendency towards unfavourable prognosis. Univariate Kap-
lan-Meier analysis was performed on basis of expression 
results from a tissue microarray. Patients with weak or 
absent nuclear FOXM1 expression (IRS = 0–1) displayed 
improved overall survival estimation (upper graph) as com-
pared to patients with strong nuclear FOXM1 expression 
(lower graph). Level of significance was only marginal (P = 
0.110; univariate log-rank analysis). IRS=Immunoreactive 
score according to Remmele et al. [23]. Crosses indicate 
censored patients.Page 6 of 9
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ies were based on in vitro experiments using only breast
carcinoma cell lines while our study analysed primary
human cancer tissue. Considering the oestrogen receptor
status we could in fact see a tendency towards negative
correlation with nuclear FOXM1 expression (P= 0.085).
As HER2-positive breast carcinomas are often associated
with negative oestrogen and progesterone receptor status
[28] these findings are in concordance with the results
from our immunohistochemistry data.
Taken together, our analyses showed FOXM1 overexpres-
sion in human breast carcinoma relative to normal breast
tissue on RNA and protein level indicating that FOXM1
may represent a novel oncogene in human breast cancer
development. Interestingly, we could find a positive cor-
relation between FOXM1 expression and HER2 status
pointing to the potential role of FOXM1 as a new drug tar-
get in HER2 resistant breast tumour. Further studies are
underway to analyse the interaction between FOXM1 and
HER2, especially whether FOXM1 directly activates the
HER2 promoter and thus inevitably leads to HER2 overex-
pression.
Conclusion
FOXM1 may represent a novel breast tumour marker with
prognostic significance that could be included into multi-
marker panels for breast cancer detection and treatment.
Interestingly, we found a positive correlation between
FOXM1 expression and HER2 status, additionally point-
ing to a potential role of FOXM1 as a new drug target in
HER2 resistant breast tumour, as FOXM1 inhibitors for
cancer treatment were recently described. Further studies
are underway to analyse the potential interaction between
FOXM1 and HER2, especially whether FOXM1 directly
activates the HER2 promoter.
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Table 1: Clinicopathological and immunohistochemical parameters in relation to nuclear FOXM1 immunoreactivity
Variable Categorisation FOXM1 immunoreactivity
n analysable negativeb positiveb pc
Clinicopathological data:
Tumour stagea
pT1 61 18 43 0.339
pT2 96 27 69
pT3 14 1 13
pT4 28 9 19
Lymph node statusa
pN0 55 28 61 0.425
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Histological grade
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G2 90 25 65
G3 87 21 66
Multifocality
unifocal tumour 174 48 126 0.820
multifocal tumour 27 8 19
Histological type
ductal 165 48 117 0.133
lobular 15 1 14
other 18 6 12
Immunohistochemistry (IHC):
Oestrogen receptor status
negative 57 9 48 0.085
positive 103 29 74
Progesterone receptor status
negative 115 27 88 0.702
positive 53 14 39
HER2 status
weak (0–2+) 154 45 109 0.045
strong (3+) 18 1 17
aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
bFOXM1 nuclear immunoreactivity: negative = IRS 0–1, positive = IRS 2–12
cFisher's exact test (two-sided), bold face representing significant data (P < 0.05)Page 7 of 9
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Table 2: Univariate analysis of factors regarding overall survival (OS) and recurrence-free survival (RFS)
Variable Categorisation Tumour-related death (OS) Tumour recurrence (RFS)
n events pc n events pc
Clinicopathological data:
Tumour stagea
pT1 61 11 0.001 59 14 <0.0001
pT2 96 34 93 43
pT3 14 5 13 7
pT4 28 17 26 18
Lymph node statusa
pN0 89 15 <0.0001 87 17 <0.0001
pN1-3 105 46 102 60
Histological grade
G1 22 5 0.003 21 6 0.001
G2 90 23 86 29
G3 87 39 85 46
Multifocality
unifocal tumour 174 55 0.165 168 70 0.348
multifocal tumour 27 12 25 12
Histological type
ductal 165 53 0.333 162 70 0.494
lobular 15 8 13 6
other 18 6 16 5
Immunohistochemistry (IHC):
Oestrogen receptor status
negative 57 24 0.027 57 29 0.057
positive 103 27 99 33
Progesterone receptor status
negative 115 49 0.001 109 52 0.015
positive 53 8 53 14
HER2 IHC
weak (0–2+) 142 42 0.055 135 53 0.120
strong (3+) 31 14 31 16
FOXM1b
negative (IRS 0–1) 56 14 0.110 54 23 0.581
positive (IRS 2–12) 146 53 140 59
aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
bFOXM1 nuclear immunoreactivity: negative = IRS 0–1, positive = IRS 2–12
cLog-rank test (two-sided), bold face representing significant data (P < 0.05)Page 8 of 9
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